As used in the Medical Psilocybin Act:

1. A. "board" means the medical psilocybin advisory board;
2. B. "clinician" means an approved health care provider licensed in New Mexico who holds a permit from the department to provide medical services to qualified patients;
3. C. "department" means the department of health;
4. D. "medical services" means services provided to a patient in an approved setting before, during and after the ingestion of psilocybin and includes a preparation session, an administration session and an integration session;
5. E. "producer" means a person who has a permit from the department to grow and harvest or prepare psilocybin from psilocybin-producing mushrooms, including to compound, convert, process or manufacture psilocybin products directly or indirectly from psilocybin mushrooms and to package or repackage or label or relabel the products;
6. F. "program" means the medical use of psilocybin program;
7. G. "psilocybin" means the naturally occurring psychedelic compound 4-phosphoryloxy-N,N-dimethyltryptamine, also known as 4-PO-DMT, and its pharmacologically active metabolite psilocin, 4-hydroxy-N,N-dimethyltryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin;
8. H. "qualified patient" means a patient whose clinician has judged the patient to be a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition;

9. I. "qualifying condition" includes:

   1. (1) major treatment-resistant depression;
   2. (2) posttraumatic stress disorder;
   3. (3) substance use disorders;
   4. (4) end-of-life care; and
   5. (5) other conditions approved by the department; and
10. J. "secretary" means the secretary of health.

History: Laws 2025, ch. 73, § 3.

ANNOTATIONS

Effective dates. — Laws 2025, ch. 73 contained no effective date provision, but, pursuant to N.M. Const., art. IV, § 23, was effective June 20, 2025, 90 days after adjournment of the legislature.